Table 1 Baseline characteristics of all participants according to TyG index tertiles

N

231

77

77

77

General information

  Age, year

81.58 ± 1.93

81.49 ± 1.69

81.77 ± 2.23

81.47 ± 1.84

0.576

  Female, n (%)

75 (32.47%)

14 (18.18%)

28 (36.36%)

33 (42.86%)

0.003

  Height, cm

165.41 ± 8.06

166.55 ± 8.03

165.17 ± 8.40

164.51 ± 7.71

0.276

  Weight, kg

67.96 ± 11.30

68.04 ± 11.89

68.12 ± 11.20

67.71 ± 10.93

0.972

  BMI, kg/m²

24.78 ± 3.42

24.44 ± 3.45

24.94 ± 3.62

24.96 ± 3.20

0.574

  SBP, mmHg

139.19 ± 21.57

139.58 ± 18.36

143.10 ± 22.03

134.90 ± 23.49

0.060

  DBP, mmHg

69.77 ± 12.06

69.64 ± 10.74

70.38 ± 12.31

69.31 ± 13.16

0.855

  LVEF, %

56.28 ± 9.19

58.26 ± 7.82

55.87 ± 9.55

54.72 ± 9.84

0.051

  Current smoking, n (%)

67 (29.00%)

27 (35.06%)

21 (27.27%)

19 (24.68%)

0.335

Laboratory markers

  eGFR, mL/min/1.73 m²

69.12 ± 20.94

72.76 ± 19.90

68.75 ± 21.27

65.85 ± 21.31

0.121

  FBG, mmol/L

8.51 ± 6.06

5.92 ± 1.68

7.75 ± 2.23

11.85 ± 9.21

 < 0.001

  UA, umol/L

354.50 ± 200.08

361.12 ± 306.02

343.06 ± 97.01

359.33 ± 133.73

0.828

  TC, mmol/L

4.03 ± 0.99

3.69 ± 0.91

4.06 ± 0.95

4.35 ± 1.01

 < 0.001

  TG, mmol/L

1.50 ± 0.77

0.93 ± 0.29

1.38 ± 0.32

2.21 ± 0.88

 < 0.001

  LDL-C, mmol/L

2.26 ± 0.85

2.00 ± 0.73

2.33 ± 0.86

2.43 ± 0.89

0.004

  HDL-C, mmol/L

1.09 ± 0.36

1.19 ± 0.47

1.09 ± 0.29

0.98 ± 0.26

0.002

  TyG index

9.01 ± 0.67

8.30 ± 0.32

8.99 ± 0.16

9.75 ± 0.43

 < 0.001

History of Past Illness

  Hypertension, n (%)

200 (86.58%)

68 (88.31%)

65 (84.42%)

67 (87.01%)

0.770

  Previous stroke, n (%)

51 (22.08%)

21 (27.27%)

17 (22.08%)

13 (16.88%)

0.299

  Previous MI, n (%)

35 (15.15%)

10 (12.99%)

15 (19.48%)

10 (12.99%)

0.431

  Hyperlipidemia, n (%)

56 (24.24%)

20 (25.97%)

16 (20.78%)

20 (25.97%)

0.686

  CKD, n (%)

37 (16.02%)

11 (14.29%)

11 (14.29%)

15 (19.48%)

0.598

Cardiovascular medications

  Aspirin, n (%)

227 (98.27%)

75 (97.40%)

76 (98.70%)

76 (98.70%)

0.775

  Clopidogrel, n (%)

220 (95.24%)

75 (97.40%)

72 (93.51%)

73 (94.81%)

0.513

  Statin, n (%)

213 (92.21%)

72 (93.51%)

68 (88.31%)

73 (94.81%)

0.282

  β-blocker, n (%)

154 (66.67%)

53 (68.83%)

52 (67.53%)

49 (63.64%)

0.776

  ACEI/ARB, n (%)

145 (62.77%)

49 (63.64%)

48 (62.34%)

48 (62.34%)

0.982

Angiography

  LAD lesion, n (%)

195 (84.42%)

69 (89.61%)

66 (85.71%)

60 (77.92%)

0.126

  LCX lesion, n (%)

150 (64.94%)

50 (64.94%)

53 (68.83%)

47 (61.04%)

0.598

  RCA lesion, n (%)

169 (73.16%)

56 (72.73%)

54 (70.13%)

59 (76.62%)

0.658

  LM lesion, n (%)

35 (15.15%)

9 (11.69%)

15 (19.48%)

11 (14.29%)

0.390

  Multivessel lesion, n (%)

180 (77.92%)

61 (79.22%)

61 (79.22%)

58 (75.32%)

0.797

  Gensini score

55.44 ± 41.43

46.55 ± 29.80

58.52 ± 43.33

61.25 ± 48.01

0.064

Treatment

0.176

  Intensive medication, n (%)

79 (34.20%)

31 (40.26%)

24 (31.17%)

24 (31.17%)

  PCI

145 (62.77%)

45 (58.44%)

48 (62.34%)

52 (67.53%)

  CABG

7 (3.03%)

1 (1.30%)

5 (6.49%)

1 (1.30%)